Analysts Offer Predictions for Novartis FY2027 Earnings

Novartis AG (NYSE:NVS) – Erste Group Bank raised their FY2027 earnings per share (EPS) estimates for shares of Novartis in a research note issued on Friday, September 18th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings of $9.81 per share for the year, up from their previous estimate of $9.80. The consensus estimate for Novartis’ current full-year earnings is $8.87 per share.

NVS has been the topic of a number of other reports. Deutsche Bank Aktiengesellschaft downgraded shares of Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Citigroup reiterated a “buy” rating on shares of Novartis in a report on Wednesday, July 22nd. HSBC raised Novartis from a “reduce” rating to a “hold” rating and boosted their target price for the company from $123.00 to $136.00 in a research note on Thursday, September 10th. Weiss Ratings restated a “buy (b)” rating on shares of Novartis in a research note on Friday, July 24th. Finally, Royal Bank Of Canada began coverage on shares of Novartis in a research note on Tuesday, September 8th. They issued a “sector perform” rating on the stock. Six investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, Novartis has an average rating of “Hold” and an average target price of $153.00.

Novartis Trading Up 0.2%

NYSE:NVS opened at $141.20 on Wednesday. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. Novartis has a 1-year low of $121.57 and a 1-year high of $170.46. The firm has a market capitalization of $269.43 billion, a price-to-earnings ratio of 21.30, a PEG ratio of 2.72 and a beta of 0.45. The business’s 50-day moving average price is $152.19 and its two-hundred day moving average price is $151.62.

Novartis (NYSE:NVS) last released its earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The company had revenue of $14.95 billion for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%.

Institutional Investors Weigh In On Novartis

Hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE lifted its holdings in shares of Novartis by 9.1% during the first quarter. Bank of America Corp DE now owns 4,962,794 shares of the company’s stock worth $758,067,000 after buying an additional 413,778 shares in the last quarter. Auto Owners Insurance Co increased its holdings in shares of Novartis by 13,687.0% during the fourth quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company’s stock worth $638,103,000 after purchasing an additional 4,594,726 shares during the period. Franklin Resources Inc. raised its position in shares of Novartis by 10.3% in the fourth quarter. Franklin Resources Inc. now owns 4,479,307 shares of the company’s stock valued at $617,562,000 after buying an additional 419,988 shares in the last quarter. Janus Henderson Group PLC grew its position in Novartis by 1.9% during the first quarter. Janus Henderson Group PLC now owns 2,275,938 shares of the company’s stock worth $347,649,000 after buying an additional 41,520 shares in the last quarter. Finally, Cullen Capital Management LLC increased its stake in Novartis by 0.5% during the 4th quarter. Cullen Capital Management LLC now owns 2,080,796 shares of the company’s stock worth $286,879,000 after acquiring an additional 10,419 shares during the period. 13.12% of the stock is currently owned by institutional investors and hedge funds.

About Novartis

Novartis AG (NYSE: NVS) is a Switzerland-based pharmaceutical company focused on discovering, developing and commercializing innovative medicines. The company’s portfolio addresses major disease areas including cardiovascular, renal and metabolic conditions, immunology, neuroscience, oncology and hematology.

Novartis markets medicines such as Entresto for certain heart conditions, Cosentyx for inflammatory diseases, Kisqali for breast cancer, Kesimpta for multiple sclerosis, Leqvio for cholesterol management, Pluvicto for certain prostate cancers and Scemblix for chronic myeloid leukemia.